Summary

More than a million people now live with Multiple Sclerosis (MS) in Europe. The personal and societal burden of MS multiplies with increasing disability. The goal is therefore to control inflammatory activity, prevent relapses and slow cumulative disability.

In this webinar, we will highlight the burden of MS, discuss its earlier diagnosis, and review the evidence for early treatment leading to better responses and a more favorable course of illness. We also examine the use of biomarkers to monitor prognosis and to anticipate treatment response and take a closer look at those with MS who may require special attention.

Agenda

SESSION 1:

Introduction

17:00 – 17:10

Prof. Celia Oreja-Guevara

SESSION 2:

The importance of an early diagnosis and the use of biomarkers to anticipate treatment response

17:10 - 17:30

Prof. Hans-Peter Hartung

SESSION 3:

Special populations in MS

17:30 - 17:50

Dr. Karen Chung

SESSION 4:

Q&A

17:50 - 18:00

Close

18:00

Know the Speakers

Prof. Celia Oreja-Guevara
MS Neurologist

Head of MS Center University Hospital San Carlos Madrid, Spain.

Prof. Hans-Peter Hartung
MS Neurologist

Chairman of the Department of Neurology Heinrich-Heine University Düsseldorf, Germany.

Dr. Karen Chung
MS Neurologist

Consultant Neurologist University College London Hospitals London, United Kingdom.

Registration form